Search - tctmd.com

Displaying 201 - 220 of 329

Sort: Relevancy | Date

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Daily News

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

L.A. McKeown

March 25, 2020

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

L.A. McKeown

March 20, 2020

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

Todd Neale

November 20, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

Caitlin E. Cox

October 02, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

Advertisement

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

Missed Opportunities: Many HF Patients Not Tested for CAD

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content